UCLA Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
NCT Number: NCT01051037
The purpose of this study is to demonstrate that combined stereotactic body radiotherapy and radiofrequency ablation is safe for patients with lung tumors near central airways.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Los Angeles, California, 90095, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
3 fraction of stereotactic body radiation therapy within 10 days.
Other names: SBR
Subject will undergo radiofrequency ablation within 10 days of the last fraction of SBRT.
Other names: RFA
Time frame: 3 years
Time frame: 3 years
Time frame: 3 years
Time frame: 3 years
Time frame: 3 years
Time frame: 3 years
Time frame: 3 years
Jonsson Comprehensive Cancer Center
Other
Phase II Study Evaluating Safety and Efficacy of Stereotactic Body Radiotherapy and Radiofrequency Ablation for Medically Inoperable and Recurrent Lung Tumors Near Central Airways
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00340405
Lung Cancer, Lung Diseases
Beijing, China
View Trial DetailsNCT03117946
Head and Neck Cancer, Head and Neck Neoplasms
Besançon, France
View Trial DetailsNCT05832008
Adherence, Patient, Behavior
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT06084208
Lung Cancer, Lung Diseases
Nijmegen, Netherlands
View Trial Details